BMJ

Antibodies to citrullinated human fibrinogen (ACF) have diagnostic and prognostic value in early arthritis

4 Sanquin Research at CLB and Laboratory of Experimental Immunology, Academic Medical Centre, Amsterdam Correspondence to: Dörte Hamann Sanquin Diagnostic Services at CLB, Dept. of Autoimmune Diseases ...
BMJ

Targeting the interleukin-5 pathway in EGPA: evidence, uncertainties and opportunities

Only a minority of patients with eosinophilic granulomatosis with polyangiitis (EGPA) can be weaned-off glucocorticoids (GC) using conventional treatment strategies. The development of biological ...
BMJ

Remission in systemic lupus erythematosus: durable remission is rare

Introduction Remission is the ultimate goal in systemic lupus erythematosus (SLE). In this study, we applied four definitions of remission agreed on by an international collaboration (Definitions of ...
BMJ

AB0727 Increased Rates of Hypertension in Patients with Psoriatic Arthritis Compared To Psoriasis Alone: Results from The UK Biobank

1 Arthritis Research UK Centre for Genetics and Genomics, Manchester Academic Health Science Centre 2 Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester ...
BMJ

Novel endotypes of antisynthetase syndrome identified independent of anti-aminoacyl transfer RNA synthetase antibody specificity that improve prognostic stratification

1 Peking University China-Japan Friendship School of Clinical Medicine, Beijing, People's Republic of China Correspondence to Dr Qinglin Peng, Department of Rheumatology, Key Lab of Myositis, ...
BMJ

Impact of anti-interleukin-6 receptor blockade on circulating T and B cell subsets in patients with systemic lupus erythematosus

1 Office of the Clinical Director, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA 2 Sjögren's Syndrome Clinic, Molecular ...
BMJ

Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs ...

Objective To assess the efficacy/safety of ivarmacitinib, a selective Janus kinase (JAK) 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis (RA) who had an inadequate ...
BMJ

Table of contents

T11: Diagnostics and imaging procedures - what’s new in imaging - miscellaneous topics T13: Furthering clinical management S1: Adaptive immunity in rheumatic diseases Adaptive immunity (T cells and B ...
BMJ

Table of contents

SpA: Innovative techniques in spondyloarthritis research – Is there light at the end of the tunnel for our patients?
BMJ

Cutaneous adverse events with febuxostat after previous reactions to allopurinol: comment on the article by Singh and Cleveland

We read with interest the recent article by Singh and Cleveland on the hypersensitivity risk of allopurinol (ALP) and febuxostat (FBX) compared with colchicine.1 A common challenge when using ALP, ...
BMJ

Is a 1-year course of methotrexate in patients with arthralgia at-risk for rheumatoid arthritis cost-effective? A cost-effectiveness analysis of the randomised, placebo ...

Objectives Rheumatoid arthritis (RA) has a considerable disease burden with life-long physical limitations, reduced work productivity and high societal costs. Trials on arthralgia at-risk for RA are ...
BMJ

Physician global assessment in systemic lupus erythematosus: can we rely on its reliability?

We read with great interest the recent paper by Aranow et al 1 about the impact of laboratory results on scoring of the Physician Global Assessment (PGA) of disease activity in systemic lupus ...